Optic Nerve Diseases: Clinical Trials

273 completed, 93 unknown, 91 recruiting, 45 terminated. 133 Phase 2, 121 Phase 1, 89 Not applicable, 65 Phase 3, 33 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	133	Completed 63, Terminated 20, Unknown 19, Recruiting 13, Active not recruiting 10, Not yet recruiting 4, Withdrawn 3, Enrolling by invitation 1
Phase 1	121	Completed 72, Terminated 13, Recruiting 12, Unknown 9, Not yet recruiting 6, Active not recruiting 4, Withdrawn 4, Enrolling by invitation 1
Not applicable	89	Completed 36, Recruiting 23, Unknown 19, Not yet recruiting 4, Active not recruiting 2, Terminated 2, Withdrawn 2, Enrolling by invitation 1
Phase 3	65	Completed 25, Recruiting 11, Unknown 11, Active not recruiting 7, Terminated 7, Withdrawn 3, Not yet recruiting 1
Phase 4	33	Completed 17, Unknown 8, Terminated 3, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Early Phase 1	16	Completed 4, Not yet recruiting 3, Recruiting 3, Unknown 3, Withdrawn 3

Follow this condition Literature Review of Optic Nerve Diseases trials Research Report on Optic Nerve Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle	Phase 2	Withdrawn	Michael, Levy M.D.,Ph.D.		2026-12-31	2025-07-16
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder	Phase 1 / Phase 2	Not yet recruiting	Tianjin Medical University General Hospital	20	2026-12-01	2026-10-16
Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis	Phase 4	Not yet recruiting	Jay C. Buckey Jr.	100	2026-11-01	2026-09-09
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related		Recruiting	Amgen	60	2026-10-15	2026-08-31
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study GLP-1 Receptor Agonist Therapy - Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity		Not yet recruiting	Istanbul Saglik Bilimleri University	28	2026-09-21	2026-09-29
Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty Lower MAP Target Strategy (50-60 mmHg), Higher MAP Target Strategy (60-70 mmHg) - Controlled Hypotension for Nasal Surgeries	Not applicable	Recruiting	Hitit University	60	2026-09-20	2026-10-14
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica	Phase 1 / Phase 2	Not yet recruiting	CRISPR Therapeutics	220	2026-09-15	2026-09-09
Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma	Phase 1 / Phase 2	Enrolling by invitation	Stanford University	90	2026-09-10	2026-10-13
Early Prediction of Outcomes Following Optic Neuritis: Development and Acceptability of a Prognostic Tool No Intervention: Observational Cohort - Optic Neuritis, Multiple Sclerosis		Not yet recruiting	King's College London	180	2026-09-01	2026-07-15
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD)	Phase 2	Not yet recruiting	Peking University People's Hospital	60	2026-08-30	2026-09-09
A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma	Phase 1 / Phase 2	Recruiting	Astellas Pharma Global Development, Inc.	156	2026-08-14	2026-09-11
DTI & DIR in Optic Neuritis MRI - Optic Nerve Disease		Not yet recruiting	Assiut University	56	2026-08-01	2026-08-06
Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy Teprotumumab N01, Intravenous Methylprednisolone (IVMP) - Thyroid Eye Disease, TED, Graves Ophthalmopathy	Phase 2	Not yet recruiting	Sun Yat-sen University	60	2026-08-01	2026-05-19
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Ravulizumab - NMOSD, Neuromyelitis Optica Spectrum Disorder	Phase 3	Recruiting	Alexion Pharmaceuticals, Inc.	19	2026-07-20	2026-09-11
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD Satralizumab - Neuromyelitis Optica Spectrum Disorders (NMOSD)		Recruiting	Junwei Hao, MD	50	2026-07-20	2026-08-13
A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy OPA1 Gene Mutation, Optic Atrophy, Autosomal Dominant		Recruiting	Ludwig-Maximilians - University of Munich	50	2026-07-16	2026-07-28
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Cenegermin, Vehicle - Non-Arteritic Anterior Ischemic Optic Neuropathy	Phase 3	Recruiting	Dompé Farmaceutici S.p.A	272	2026-07-01	2026-09-10
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG)	Phase 1	Not yet recruiting	The Affiliated Hospital of Qingdao University	18	2026-07-01	2026-06-30
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial Crisugabalin, Placebo+Crisugabalin - Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain	Phase 4	Not yet recruiting	Tang-Du Hospital	110	2026-06-15	2026-07-13
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis	Phase 3	Recruiting	Oculis	210	2026-05-28	2026-08-14

Showing 20 of 582. Sign in to see all of them.

Narrower conditions

Neuromyelitis Optica (171)  ·  Multiple Sclerosis (89)  ·  Optic Neuritis (87)  ·  Optic Nerve Glioma (82)  ·  Astrocytoma (74)  ·  Low Tension Glaucoma (65)  ·  Medulloblastoma (56)  ·  Oligodendroglioma (56)  ·  Familial ependymoma (55)  ·  Central Nervous System Neoplasms (46)  ·  Glaucoma (46)  ·  Optic Neuropathy, Ischemic (46)  ·  Optic Atrophy, Hereditary, Leber (44)  ·  Choroid Plexus Neoplasms (42)

Broader conditions

Eye Diseases (564)  ·  Cranial Nerve Diseases (518)  ·  Nervous System Diseases (511)  ·  Immune System Diseases (243)  ·  Autoimmune Diseases (214)  ·  Demyelinating Autoimmune Diseases, CNS (208)  ·  Autoimmune Diseases of the Nervous System (202)  ·  Demyelinating Diseases (196)  ·  Myelitis, Transverse (156)  ·  Optic Neuritis (154)  ·  Neoplasms by Site (123)  ·  Nervous System Neoplasms (122)  ·  Neoplasms (121)  ·  Central Nervous System Diseases (118)

Interventions

Carboplatin (13)  ·  Methylprednisolone (13)  ·  Filgrastim (11)  ·  Temozolomide (11)  ·  inebilizumab (8)  ·  Cyclophosphamide (7)  ·  Etoposide (7)  ·  Rituximab (7)  ·  Tomography, Optical Coherence (7)  ·  eculizumab (7)  ·  satralizumab (7)  ·  Adrenal Cortex Hormones (6)  ·  Azathioprine (6)  ·  Brimonidine Tartrate (6)  ·  Granulocyte Colony-Stimulating Factor (6)

Sponsors

National Cancer Institute (NCI) (25)  ·  Tianjin Medical University General Hospital (14)  ·  Children's Oncology Group (12)  ·  Alexion Pharmaceuticals, Inc. (9)  ·  Fondation Ophtalmologique Adolphe de Rothschild (8)  ·  GenSight Biologics (8)  ·  National Eye Institute (NEI) (8)  ·  Pediatric Brain Tumor Consortium (8)  ·  Santhera Pharmaceuticals (8)  ·  Tongji Hospital (7)  ·  Universitaire Ziekenhuizen KU Leuven (7)  ·  Washington University School of Medicine (7)  ·  Chinese PLA General Hospital (6)  ·  Duke University (6)  ·  Third Affiliated Hospital, Sun Yat-Sen University (6)

Countries

United States (239)  ·  China (96)  ·  France (67)  ·  Canada (53)  ·  United Kingdom (46)  ·  Germany (43)  ·  Italy (38)  ·  Australia (27)  ·  Spain (23)  ·  South Korea (22)  ·  Belgium (18)  ·  Turkey (Türkiye) (17)  ·  Poland (16)  ·  Switzerland (15)  ·  Denmark (14)

Top investigators

Michael Levy, MD, PhD (7)  ·  Fu-Dong Shi, MD,PhD (4)  ·  Ingeborg Stalmans, MD, PhD (4)  ·  Elizabeth Fox, MD (3)  ·  Harry T Whelan, MD (3)  ·  Henry S. Friedman, MD (3)  ·  Jeffrey L Goldberg, MD PhD (3)  ·  Junwei Hao, MD (3)  ·  Wei Wang, MD (3)

Results publications

PMID 36449262, PMID 34108929, PMID 40743487, PMID 26199618, PMID 26604914, PMID 26606867, PMID 26892229, PMID 27857759, PMID 27904503, PMID 30194931, PMID 33676197, PMID 34498507, PMID 36007339, PMID 36724181, PMID 40288333, PMID 10393040, PMID 10653426, PMID 11849670, PMID 12126947, PMID 12383810, PMID 12395089, PMID 12511365, PMID 1454314, PMID 1463007, PMID 15269289, PMID 15350316, PMID 15814645, PMID 15980233, PMID 16123421, PMID 16234526, PMID 16249495, PMID 16249960, PMID 16408203, PMID 16533779, PMID 16638802, PMID 1674640, PMID 16831964, PMID 16899778, PMID 16908813, PMID 16914576, PMID 17532502, PMID 17607354, PMID 17610262, PMID 17634493, PMID 17941066, PMID 17998042, PMID 18048828, PMID 18281544, PMID 18281546, PMID 18441370

NIH funding

U01CA081457 (9), U01CA097452 (8), U10CA098543 (6), 2019 (5), 2017 (4), 2014 (3), 2015 (3), 2018 (2), 2023 (2), U10CA081920 (2), 2005 (1), 2008 (1), 2025 (1), K23EY026098 (1), P30CA012197 (1)